The health care investing scene in London
London's health care investor base is deep, and it's younger than a lot of founders expect. Investors focused on pre-seed, seed, and early stage venture rounds outnumber Series A and later checks by roughly three to one, so if you've got a health care idea and you're still pre-revenue, you're not underdressed for this market. You're actually in the room the city is built for.
Most of that early money sits with venture capitalists and private equity investors rather than individual angels, though there's a real angel community here too. A lot of the private equity tag on London profiles actually points to individual investors who write checks personally rather than through a fund, so don't assume every private equity investor you find wants a control stake or a board seat before they'll talk to you.
London also sits inside the UK's "Golden Triangle," the corridor between London, Oxford, and Cambridge that produces most of the country's academic health science spinouts. If your startup touches deep biotech or therapeutics rather than health software, it's worth widening your search to biotechnology investors too, since a lot of London-based funds write checks across the whole triangle instead of staying inside the M25.
What London health care investors look for
London health care investors care about evidence more than almost any other market on this list. A growing user base is nice, but it's not what gets a term sheet here. What gets a term sheet is a pilot with real clinical or health outcomes data, even a small one, and a plan for how you get through UK regulatory approval if your product needs it.
If your product counts as a medical device or makes a clinical claim, you'll need to think about MHRA or UKCA approval earlier than you'd expect in most markets. Investors here have seen enough health care startups stall out waiting on regulatory sign-off that they'll ask about your regulatory pathway in the first meeting, not the fifth.
Check sizes follow the same range you'd see anywhere else. Angels write $25,000 to $500,000, and venture checks run from $2 million to $100 million or more depending on stage. What changes in London isn't the size of the check, it's what you need to show before anyone writes it. Building your list in AngelMatch's investor database lets you filter for health care investors who've actually backed regulated products before, instead of guessing from a LinkedIn bio.
Approaching health care investors in London
The single strongest proof point you can bring to a London health care investor is a signed pilot with an NHS trust, even a tiny one. The NHS has a reputation for slow procurement, so if a trust has agreed to work with you, an investor reads that as evidence your product has already survived the hardest sales cycle in UK health care. Lead with it in the first two lines of your email.
Timing matters more here than founders expect. London slows down hard in August, when a lot of the city, and Parliament, is on holiday, and again over the last two weeks of December. If you can, get your first meetings booked before the summer and save the follow-ups for September.
Warm intros go further than cold outreach, and the easiest ones to get run through London's academic clusters. Imperial College London, UCL, and King's College London all run health care incubators and accelerator programs, and a lot of London's health care investors sit on advisory boards or judging panels for them. If you've got any connection to one of those programs, even a guest lecture, use it.
On dilution, expect the same range you'd see anywhere else, typically 15% to 25% in an early round. Once you're past a first meeting, keeping your data room and cap table organized in one place, rather than emailing PDFs back and forth, makes the diligence part move faster.
London's health care investors reward founders who show up with evidence, not just a deck. If you've got a pilot, even a small one, and a rough sense of your regulatory path, you're already ahead of most of the founders reaching out to this city's investors. Build your list from real, current investor data, then run your outreach through a system built for it instead of a scattered spreadsheet. AngelMatch's email outreach tools can help you track who's replied and who's still worth a follow-up.
Health care investors
